Webinar—Into the Neural Crystal Ball

Chapters 00:00 Introduction to CNS Drug Development 01:49 Clinical Trials Today and Tomorrow: Trends, Challenges, and Future Directions 04:56 The Role of Small Molecules in Future Therapies: Focus Areas in Psychiatric Indications 10:18 The Psychedelic Pipeline: Targets and Divergence 15:49 Challenges Facing Psychedelic Integration 19:06 Clinical Trials Today and Tomorrow: Trends, Innovation, and What’s Next 20:53 Advancements in Device-Based Interventions 27:21 The Aspirational Endpoint of Prevention 28:27 Major Trends in CNS Growth 29:22 Conclusion and Q&A Session Engage in a forward-looking discussion on the evolution of CNS drug development, examining how innovation, regulation, and technology are converging to shape the future of small molecules, biologics, psychedelics, devices, and AI-driven discovery. Central nervous system (CNS) drug development is entering a transformative era, driven by advances in small molecules, biologics, psychedelics, devices, and artificial intelligence (AI). The global CNS therapeutics market is projected to more than double over the next decade, fueled by rising neurological and psychiatric disease prevalence, improved drug development processes, and increased investment in research and digital health. Despite significant challenges, including complex brain biology, high placebo effects, and low clinical trial success rates, innovations in precision medicine, biomarkers, and AI are accelerating progress. This presentation provides a comprehensive overview of current trends, emerging therapies, and future outlooks in CNS drug development. It discusses how Altasciences leverages operational efficiencies and technological advancements to support the evolving pipeline of CNS compounds. What you will learn: 1. Gain insight into the latest trends, challenges, and innovations shaping the future of CNS drug development. 2. Explore emerging therapeutic approaches, including small molecules, biologics, psychedelics, devices, and artificial intelligence, and their impact on clinical practice. 3. Understand how advances in precision medicine, biomarkers, and digital health are transforming CNS clinical trials and patient outcomes. Who may this interest? Pharmaceutical and Biotech executives, scientists, clinicians, and regulatory/medical affairs specialists developing drugs for neurological or psychiatric indications. Presented by Beatrice Setnik, PhD, Chief Scientific Officer, Altasciences Dr. Setnik has been working in the area of clinical drug development and abuse potential (AP) assessment since 2005. Dr. Setnik is currently the Chief Scientific Officer at Altasciences and an Adjunct Professor at the University of Toronto (Department of Pharmacology and Toxicology). Dr. Setnik earned her doctorate degree in Pharmacology and the Collaborative Program in Neuroscience from the University of Toronto in 2005. She has published numerous research articles in internationally recognized peer-reviewed journals and is a recognized expert in the field of human abuse and physical dependence potential evaluation.